Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Lapisteride
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C29H40N2O3 |
Molar mass | 464.650 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase. It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia, but was never marketed.
See also
Drugs used in benign prostatic hyperplasia (G04C)
| |
---|---|
5α-Reductase inhibitors | |
Alpha-1 blockers | |
Steroidal antiandrogens | |
Herbal products | |
Others |